Previously, we showed blocking Gi/o-GPCR signaling also enhances the sensitivity of the bulk of HER2+ breast cancer cells to HER2-targeted therapy, suggesting targeting Gi/o-GPCRs may have dual inhibitory effects on both CSCs and non-CSCs [23]. Here, ERBB2 is linked to breast carcinoma.